Wave Life Sciences reports updated WVE-006 RestorAATion-2 data for AATD
Wave Life Sciences released updated clinical data from the ongoing Phase 1b/2a RestorAATion-2 trial of WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency, and said it expects FDA feedback on a potential accelerated approval pathway in mid-2026. The data are early-stage, from small cohorts of eight patients each, and the company has not reported a trial outcome or regulatory decision, so the update's significance for shareholders depends on future regulatory and clinical results.
Key points
- Single-dose 200 mg, 400 mg and 600 mg cohorts reached Z-AAT reductions of 47.3%, 49.7% and 59.1% from baseline, per the filing.
- Multidose 200 mg biweekly cohort reached 70.5% Z-AAT reduction and total AAT of 11.9 µM; 400 mg monthly cohort reached 67.7% reduction and 13.6 µM.
- Company expects FDA feedback on a potential accelerated approval pathway mid-2026 and data from the 600 mg multidose cohort in the second half of 2026.
- All adverse events were mild to moderate, with no serious adverse events, according to the company.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.